Last reviewed · How we verify
Miscible liquid of dexamethasone and ropivacaine
Miscible liquid of dexamethasone and ropivacaine is a Small molecule drug developed by Beijing Tiantan Hospital. It is currently FDA-approved.
The drug, a miscible liquid of dexamethasone and ropivacaine, is currently marketed by Beijing Tiantan Hospital. Its key strength lies in the unique combination of dexamethasone and ropivacaine, which may offer enhanced efficacy or safety profiles compared to monotherapy. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Miscible liquid of dexamethasone and ropivacaine |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-craniotomy Pain (PHASE4)
- Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-Craniotomy Pain in Children (PHASE4)
- Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Postoperative Pain After Craniotomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Miscible liquid of dexamethasone and ropivacaine CI brief — competitive landscape report
- Miscible liquid of dexamethasone and ropivacaine updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI